| Literature DB >> 11128651 |
D A Nicoll-Griffith1, J A Yergey, L A Trimble, J M Silva, C Li, N Chauret, J Y Gauthier, E Grimm, S Léger, P Roy, M Thérien, Z Wang, P Prasit, R Zamboni, R N Young, C Brideau, C C Chan, J Mancini, D Riendeau.
Abstract
Metabolites of the COX-2 inhibitor rofecoxib (MK-0966, Vioxx) were prepared by synthetic or biosynthetic methods. Metabolites include products of oxidation, glucuronidation, reduction and hydrolytic ring opening. Based on an in vitro whole blood assay, none of the known human metabolites of rofecoxib inhibits COX-1 nor contributes significantly to the inhibition of COX-2.Entities:
Mesh：
Substances：
Year: 2000 PMID： 11128651 DOI： 10.1016/s0960-894x(00)00538-2
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823